As an Associate Partner in L2 Consulting, Mark comes with an established track of CRO business development leadership spanning more than 20 years.  As Vice President of Business Development for many of the preclinical CROs he has established a firm understand of he strengths and weaknesses of each. He is instrumental is matching the right CRO to the right study set.  He spent over 13 years at The Perkin Elmer Corporation including time at involved the the introduction both PCR and LC/MS/MS technology. Many director of early development and preclinical consultants seek his advice in placing IND and other preclinical programs.